Genetic Testing Recommendations for Triple Negative Breast Cancer

This research article discusses genetic testing for triple negative breast cancer (TNBC), focusing on the implications of multigene panel testing (MGPT). The study, a collaboration between Ambry Genetics, Mayo Clinic, and the Triple Negative Breast Cancer Consortium, identifies genes beyond BRCA1 associated with increased TNBC risk. Current guidelines recommend BRCA1/2 testing for women diagnosed with TNBC under 60 years of age. However, the findings suggest that MGPT should be considered for all women diagnosed with TNBC, regardless of age or family history. The article outlines the characteristics of TNBC, including its prevalence and associated risks. It emphasizes the importance of identifying germline mutations to guide medical management and mentions that many genes linked to TNBC have established guidelines for increased screening and surgical intervention. The study assessed 10,901 women with TNBC and found significant associations between various genes and TNBC risk, highlighting the need for broader genetic testing protocols.